Why Is Moderna (MRNA) Stock Rising Today? $2.25B Patent Settlement

Moderna (MRNA) shares are surging on Wednesday after the biotechnology giant announced it has reached a landmark settlement agreement with Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma to resolve a long-running patent dispute over the lipid nanoparticle (LNP) delivery technology that underpins its COVID-19 vaccine, Spikevax.

The deal, worth up to $2.25 billion in total, removes a major legal overhang that had weighed on the stock for years. Investors reacted positively to the resolution, which also provides Moderna with a clearer financial roadmap through the end of 2026 and beyond.

The $2.25 Billion Settlement: What You Need to Know

Moderna announced late Tuesday that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences, resolving all litigation worldwide related to its Spikevax and mResvia vaccines. Under the terms of the deal, Moderna will make a lump-sum payment of $950 million in the third quarter of 2026, with no future royalties owed after that payment is made.

The $950 million charge is expected to be recorded in Q1 2026, though Moderna stated it does not consider any additional loss probable at this time. The dispute centered on lipid nanoparticle (LNP) delivery technology — a critical component that acts as a protective shell to deliver fragile mRNA molecules into human cells, making mRNA vaccines like Spikevax possible.

Arbutus and Genevant had alleged that Moderna used their patented LNP technology without authorization in developing its COVID-19 shot, and pursued legal action across multiple jurisdictions worldwide. The settlement resolves all of those global claims in one agreement. There remains a conditional element to the deal: Moderna is continuing its appeal to the Federal Circuit Court of Appeals, arguing that its status as a government contractor limits its liability under federal statute (28 U.S.C. § 1498).

If Moderna loses that appeal, it has agreed to make an additional payment of up to $1.3 billion within 90 days of the decision, bringing the potential total to $2.25 billion. However, if Moderna ultimately prevails in further proceedings, whether en banc, at the Supreme Court, or on remand, Arbutus and Genevant have agreed to refund that additional payment in full, plus interest.

Arbutus and Genevant described the agreement as the largest disclosed patent settlement in pharmaceutical history and the second-largest across all industries.

Join our Telegram group and never miss a breaking digital asset story.

MRNA Stock Snapshot: Price, Trends, and Key Metrics

As of the morning of March 4, 2026, Moderna shares were trading around $52.85–$53.02, up approximately 6% on the day from a previous close of $49.83, with an intraday high of $56.60. The stock had initially surged more than 8–10% in after-hours trading on Tuesday night following the settlement announcement before settling into its current trading range.

The market cap stands at approximately $20.94 billion, and trading volume came in at roughly 3.96 million shares — well below the average daily volume of approximately 11.8 million, suggesting the move was driven more by sentiment than heavy institutional repositioning.

From a performance standpoint, MRNA has been a standout year-to-date, posting a gain of nearly 80% in 2026 compared to the S&P 500’s slight decline of 0.25% over the same period. On a one-year basis, the stock is up approximately 74.58%, far outpacing the broader index. However, the longer-term picture remains challenging, MRNA is still down roughly 63% over three years and nearly 60% over five years, reflecting the dramatic post-pandemic correction the stock endured after its COVID vaccine-era highs.

Looking ahead, Moderna now expects to end 2026 with $4.5 to $5.0 billion in cash and cash equivalents, and retains access to up to $900 million under its existing credit facility, putting total projected liquidity at $5.4 to $5.9 billion. CEO Stéphane Bancel expressed confidence that the company will return to revenue growth in 2026 and reach breakeven by 2028, with potential catalysts including FDA approval of a flu-plus-COVID combination vaccine and a standalone flu vaccine, as well as clinical trial data expected in cancer and rare disease indications.

Analyst sentiment remains mixed. The average price target sits at $42.25, below the current trading price, though the most recent rating from Piper Sandler maintains an Overweight rating with a raised price target of $69.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.